MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Clinical trials for MULTIPLE SCLEROSIS, RELAPSING-REMITTING explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE SCLEROSIS, RELAPSING-REMITTING trials appear
Sign up with your email to follow new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
MS drug trial for japanese patients halted early
Disease control TerminatedThis study tested a drug called natalizumab, given as a shot under the skin every 4 weeks, in Japanese adults with relapsing-remitting multiple sclerosis (MS). The goal was to see if it could reduce new brain lesions over 24 weeks. The trial was stopped early, and only 21 people …
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 26, 2026 07:02 UTC
-
MS drug trial halted early after only 8 volunteers
Disease control TerminatedThis phase 2 trial tested an experimental drug called RC18 in people with relapsing-remitting multiple sclerosis (MS). The goal was to see if RC18 is safe and can reduce the number of MS attacks. Only 8 people took part before the study was stopped early. The drug works by target…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 06:44 UTC